Rapid coagulation and fibrinolysis assays suitable for use with an imprecisely measured sample volume (either whole blood or plasma) have been developed, utilizing a technology based on paramagnetic iron oxide particles (PlOP) that move in response to an oscillating magnetic field. PlOP are combined with appropriate test reagents for clotting and thrombolysis assays and formulated as dry reagents within a capillary test chamber. The minima and maxima of the PlOP oscillations define a two-sided waveform that provides kinetic information on fibrin polymerization and lysis. Subject to the chemistry of the dry reagent formulation, the resulting waveform can be used to define clotting time, lysis onset time, or fibrinogen variables. Applications to one-stage prothrombin time and one-stage activated partial thromboplastin time tests have yielded assays with consistently good correlations with other test methods. Applications to fibrinolysis studies have yielded global assays of thrombolytic activity, in that the assay results reflect the interactions of multiple factors associated with the effectiveness of thrombolytic therapy. Depending on the components utilized in a particular reagent formulation, one can derive information about the activity of such factors as fibrinogen, plasminogen, and related inhibitors, as well as the lytic agent being administered. Use of these assays in a clinical setting should provide a rapid, convenient alternative to conventional testing of coagulation variables and a reliable method for monitoring thrombolytic therapy.
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With the increased use of anticoagulant and fibrinolytic drugs, rapid assessment of the status of blood coagulation and fibrinolysis is essential for effective patient management.
At present, no simple and rapid diagnostic systems reliably monitor these variables on a decentralized basis (1). Conventional laboratory methods are often inadequate because of in vitroartifacts of fibrinolytic therapy such as the continued conversion of plasminogen to plasmin, the subsequent degradation of fibrinogen, and other factors (2) (3) (4) . In addition, the turnaround time of these assays is often too slow to provide the essential information when needed.
We have developed blood coagulation and fibrinolysis assays suitable for bedside use by means of an alternative technology that overcomes the shortcomings of the current methods. The test system we describe is compact and easy to use;requires only a small volume of whole blood or plasma (at least 30 p.L), which need not, be precisely pipetted; and incorporates the advantages of dry reagent or "solid phase" assay systems: stability, reproducibility, and convenience (5) .
MaterIals and Methods

Principle.
The system consistsof a microprocessorbased analyzer and individualdisposable"testcards."
To measure clotting and lysis, the method makes use of inert paramagnetic particles, typically <1 m in diameter, dispersed in a dry reagent. These microscopic particles tend to align with, and are attracted toward, an applied magnetic field (6) .The paramagnetic iron oxide particles (PlOP), in combination with the biochemicals necessary for the reactions, are contained within a flat capillary chamber that defines the reaction volume.1 The thickness and shape of this chamber are determined by a spacer situatedbetween an optically transparent cover piece and a plastic base. A sample well isconnected to the reaction chamber by means of a capillary conduit.
Each testcard has a magnetically encoded stripeon the back, containing lot-specific information such as test type, lot number, expiration date, and calibration data. Encoded information is entered electronically by passing the test card through the stripereader on the top of the instrument.
The test card is then placed in the analyzer. The sample is dropped into the sample well and is drawn via capillary action into the reaction chamber, which is maintained in a temperature-controlled37#{176}C environment.
The sample entering the reaction chamber dissolves the reagent and signals the beginning of the timing sequence. The PlOP are then freed from the dry reagent matrix and are driven into oscillationby the presence of orthogonal magnetic fields, one of which isvaried with time. The movement of the particles is monitored optically throughout the reaction. Figure 1 A decay in the amplitude after an initial period of maximum oscillation corresponds to the onset of coagulation (conventional coagulation test "endpoint"). This decay results from restriction of the movement of the PlOP as they become entrapped by the polymerizing fibrin network. Continued monitoring of the particle oscillations after clotting has occurred reveals subsequent changes in clot structure, such as degradation by fibrinolytic agents. Analysis of features in the waveform provides a method for quantifying fibrinolysis. The analyzer may report a "clotting time" result, a "lysis onset time" (LOT) result, or both (seeFigure 2b) after microprocessor analysis of the waveform amplitude characteristics by use of algorithms developed to reproducibly determine these points.
Instruments. interactions. Waveforms for coagulation assays are essentially the same as the "clotting phase" of the waveform (Figure 2 ).Once the analyzer has determined the clotting time, it automatically transforms or "maps" the data onto a different coordinate system for standardization to a particularwet-chemistry reference method.
The calibrationfactorsnecessary for the analyzer to make this transformation are encoded magnetically on each testcard.These factors also compensate for minor lot-to-lot variations in reagent formulation and, if necessary, could be used to calibrate vs a particular local comparison method. Figure 3 illustrates data before and after this transformation for a PT comparison study conducted at a major medical center laboratory. Citrated whole-blood samples or citratedplasmas from the same samples were tested with the COAG-1 System and a Coag-A-Mate X-2 instrument, respectively. In a second study, determination of the PT values in 271 patients' plasma samples by the COAG-1 System and the Coag-A-Mate X-2 yielded a correlation coefficient (r) of 0.96 (data not shown). In another study (7), the drychemistry PT assay was compared with conventional methods for 297 patients' samples at several testing sites, yieldingsimilarresults.
We explored the ability of the COAG-1 System to effectively analyze severalsample types. Table 1 shows PT test resultsin an early study comparing four different blood sample types: capillary, nonanticoagulated blood; venous, nonanticoagulated blood; citrated whole blood;and citrated plasma. Multiple samples obtained from one normal volunteer at various times were tested on seven different instruments, all within 30 mm of sample collection. As these resultsshow, any ofthe four sample types can be used with equal effectiveness. The effect of various hematocrit values, from 0% (plasma) to 57%, was found to be insignificant in PT determinations.Platelet concentration also had no significant effect on the PT result.
Application
to APTT measurements.
The one-stage COAG-1 APF System was compared with a conventional two-stage method for plasma samples from 83 patients (Figure 4) . Citrated whole blood also may be utilized with the dry reagent system, as seen in Table 2 , where representative data for within-run precision studies are presented.
As for PT, wide variation in hematocrit or in platelet concentration had minimal effect on the APP'F (data not shown).
Application to thrombolysis
assays. To measure clot lysis with this technology, the instrument monitors Finger-puncturesamples were obtained with an Autolet automatic bloodsampling device (Uster Scientific); venous blood sampleswere obtainedwith use of a single syringe. Some of the blood samplewas used to fill evacuated tubes containingsodiumcitrate. Some citratedblood was centrifugedto obtain the plasma and some was tested directly. particle oscillation until an increase in amplitude after a period of minimum oscillations signals the onset of fibrinolysis. The point of increase in amplitude is defined as the lysis onset time (LOT). Assays of the thrombolytic activityof both exogenously and endogenously applied thrombolytic drugs have been devised. In the "exogenous" assay (so-called because the plasminogen activator is not incorporated into the clot), the test card contains a dried, preformed fibrin clot with paramagnetic particles incorporated. This assay, which is independent of the amount of fibrinogen in the sample, allows evaluation of the activity of the thrombolytic drug in a patient's sample in comparison with a uniform standardized clot. The typical exogenous assay waveform shown in Figure 5 is that from a sample of citrated whole blood with rt-PA added in vitro. The LOT decreases with increasing concentrations of rt-PA in the sample (Figure 6a) .
Alternatively, an "endogenous" assay may be performed by adding a blood sample containing a throm- bolyticagent to a test card containing a thrombin-or snake venom-based dry reagent without a preformed clot; here, the patient's sample forms its own clot. The waveform produced by a typical endogenous assay was shown in Figure 2a ; Figure 6b shows data for a reptilase-based endogenous assay.
As does the exogenous assay, the endogenous assay reflects rt-PA concentrations; i.e., LOT values decrease with increasing concentrations of rt-PA. A straight-line relationship for the data in Figure 6b using the endogenous assay with aliquots of a citrated whole-blood sample to which is added a thrombolytic agent-rt-PA or others-at severalconcentrationsspanning the therapeutic range. Figure 8 shows the various responses of five normal volunteer donors to three commonly used fibrinolytic drugs.
Fibrinogen estimation.
Another application of the thrombinor reptilase-based assay involves kinetic analysis of the clotting waveform to measure the concentrations of fibrinogen. Kinetic analysis had been applied previously to turbidity measurements during fibrin polymerization in plasma to determine fibrinogen concentrations (8) . In the COAG-1 dry reagent system, samples with greater concentrations of fibrmogen may be expected to produce denser fibrin clots than those 100 . 5 6 7 8 9 10 11 12 13 14 15
Urokinase (x103 U/I) The denser clots would restrictparticleoscillation to a greater degree, thereby resulting in a lower minimum oscillation signal value (designated "B") relative to the maximum oscillation signal (A) value. Figure 9 shows the relative positions and magnitudes of A and B in a sample waveform.
Preliminary analysis of the parameters A and B indicates that the numerical value of (A-B)/A correlates well with relative concentrations of fibrinogen, as shown in the upper curve in Figure 10 . For a more linearized measure of fibrinogen at abnormally low concentrations, we utilize the parameter A/B (lower curve in Figure 10) or B/A. This assay thus provides a good estimate of fibrinogenconcentrations below the normal range, producing clinically useful information regarding the effects of ongoing thrombolytic therapy.
DiscussIon
The diagnostic assay technology described here is rapid, convenient, and applicable to measurements of both blood coagulation and fibrinolysis. Relatively small volumes of whole blood or plasma are required. The technology provides kinetic data on clot formation that are analogous to those obtained with other methods. This technology was first applied to measurement of PT and compared with conventional PT methods. In studies of >500 patients, correlations with conventional wetchemistry coagulation results for PT were good. In many of these studies, the raw data were transformed to give the shorter clotting time values of the conventional methods. One could, in principle, utilize the transformation capabilities of the instrument to obtain the International Normalized Ratio, particularly for the subgroup of patients being treated with oral anticoagulanta.
The technology applied to APTF compared favorably with conventional two.stage APT.F measurements, indicating that the dry chemistry test card can be configured to provide a one-stage AP'I'F test. This is a significant advantage over other methods, and offers greater convenience for decentralized testing than would a twostage method. For monitoring fibrinolysis, a disadvantage of conventional clot lysis measurement methods has been the difficulty in yielding quantitative data and simultaneously providing a convenient test format. Conventional clot lysis assays have included euglobulin lysis time, dilute blood or plasma clot lysis time, fibrin plate methods, lysis of labeled fibrin substrates, thromboelastography, the rising bubble method, caseinolytic methods, and others (9-i 7) . Clot lysis methods generally measure the time required to achieve clot dissolution or the kinetics of clot breakup. The information derived from the clot lysis measurement we developed may be somewhat different from that obtained from other clot lysisbased methods, in that the COAG-1 System measures the time required to reach the onset of lysis.
LOT is a reproducible kinetic variable that allows measurement of clot lysis in whole-blood samples for endogenously or exogenously applied thrombolytic drugs. In the endogenous thrombolytic drug assay, a fresh clotis formed from the blood sample and monitored for lysis, automatically.
We When exogenously applied thrombolytic agent is used with the dry "standardized clot" test described here, a more-specific functional assay may be provided. Such an assay could be used to rapidly quantify the systemic thrombolytic agent concentration. A straight-line relationship, (LOT)2 = K'/[rt-PA], for the data in Figure 6a may be derived from a kinetic model, where K' is a kinetic rate constant. This relationship is similar to that derived from a different but analogous model used to describe synthetic substrate-based plasminogen activator assays (18). Eventually, concentrations of other analytes, e.g., total available plasmin (EC 3.4.21.7), may be determined by using standardized clotassays of this type. The exact functional assay would depend on the rate-limiting dry-chemistry formulation of the test card. Preliminary data suggest that a rapid, convenient fibrinogen assay may be developed for use with a citrated whole-blood sample that is otherwise undiluted. This assay would be useful in assessing the risk of bleeding for patients undergoing thrombolytic therapy, because severe fibrinogen depletion is a risk factor for bleeding. Currently, turnaround times for fibrinogen assays are typically long, and results may be outdated by the time they reach the physician.
A rapid-turnaround fibrinogen assay may also be important in treating the bleeding patient. Currently, samples obtained during thrombolytic therapy and not analyzed immediately may require the addition of inhibitors of either plasminogen activator or plasmin to minimize the in vitro artifacts that arise from plasminogen activation. This, however, restricts the kinds of diagnosticteststhat may be performed on that sample (19). Because the assays performed with the technology described in this reportare rapid and can be performed without delay at the patient's bedside, adding inhibitors to the samples should not be necessary.
